Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQX:ATBPF) filed its financial and operating results today for the fiscal quarter ended December 31, 2014. The Corporation's unaudited Q3 2015 financial statements and MD&A are available on SEDAR.

The Company also announced that Jonathan Ross Goodman has resigned from the Company's Board of Directors, effective today. Mr. Goodman has been a Director since June 2013. Samira Sakhia will replace Mr. Goodman as chair of the Audit Committee.

Mr. Goodman stated, "It has been a pleasure working with Antibe's management and Board; they are an extremely talented group. My duties at Knight Therapeutics are simply too great to continue these additional responsibilities. I look forward to remaining connected with the team."

"Antibe's management and shareholders would like to thank Jonathan for his contributions to the company, the Board, and its shareholders. We look forward to maintaining a close working relationship with Jonathan and his business enterprises, and are grateful that he has offered continued assistance." said Walt Macnee, Chairman of Antibe's Board of Directors.

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe's technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe's lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe's pipeline, targets the urgent global need for a safer analgesic for severe acute pain.

www.antibethera.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Important Note on Forward Looking Statements

Copyright Business Wire 2010